Is RenalNext the right test for you?
If several members of your family have had kidney (renal) or thyroid cancers – or maybe kidney or neuroendocrine tumours, this test is all about early detection and risk reduction.
It involves analysis of a 19 gene panel designed to provide more precise data to guide you about additional screening or risk reduction. It can also highlight if other members of your family may be at risk.
To get this test you will first need a consultation with your clinician, then you can either:
- Buy it directly from this website (this cost may be covered by your medical insurance).
- Access it through your treating hospital/private healthcare provider.
This test is only available to those aged 18 years or above.
- Why?►Close tab
Would more frequent screening help you?
This test can help your clinician decide at what age and how often you should have screening for renal and other cancers
This test can also indicate if other member of your family may have hereditary risk of developing renal or other cancers – and therefore what steps they need to take for further screening or monitoring.
You can discuss this with your clinician, or if you would like to talk to one of our experts about the test, call us on +44 (0) 7495 981816
- How?►Close tab
What do I need to do?
It’s usually a simple ‘spit test’ – all we need is your saliva. You’ll receive a kit with clear instructions on giving your sample.
- Process►Close tab
Buying the test
Step 1: There are two options:
- Via your treating hospital/private healthcare provider (we have special arrangements with many healthcare providers to enable you to access this test, click here to see the list)
- By clicking the ‘Buy direct now’ button above (the cost may be covered by your medical insurance – check your policy details)
Step 2: Collection of sample
We will liaise directly with your clinician and organise the collection of your sample and delivery to the laboratory.
Step 3: Analysis and reporting
Your sample will be analysed and a report will be generated, usually within four to five weeks of receipt of your sample in the laboratory.
Step 4: Results
Your clinician will receive the test report giving a clear indication of whether you are at risk of kidney (renal) cancer and what steps you – and possibly other members of your family – need to take next.
- Clinicians►Close tab
Is RenalNext the right test for your patient?
RenalNext is a next generation sequencing panel that simultaneously analyses 19 genes associated with increased risk for kidney cancer.
When to consider testing
- Early-onset kidney cancer (diagnosed <46 years of age)
- Multiple primary cancers in one person (e.g. 2 primary kidney cancers or kidney and thyroid cancer)
- >2 family members* with kidney cancer OR >3 family members* with kidney and other cancers
- Multiple close family members* with kidney and neuroendocrine tumours
* On the same side of the family
Mutation Detection Rate
RenalNext can detect >99.9% of described mutations in the included genes, when present (analytic sensitivity).
- Test Description
RenalNext analyses 19 genes (listed above). 18 genes (excluding EPCAM) are evaluated by next generation sequencing (NGS) or Sanger sequencing of all coding domains, and well into the flanking 5’ and 3’ ends of all the introns and untranslated regions. In addition, sequencing of the promoter region is performed for the following genes: PTEN (c.-1300 to c.-745), MLH1 (c.-337 to c.-194), and MSH2 (c.-318 to c.-65). For MITF, only the status of the c.952G>A (p.E318K) alteration is analysed and reported. The inversion of coding exons 1-7 of the MSH2 gene is detected by NGS and confirmed by PCR and agarose gel electrophoresis.
Clinically significant intronic findings beyond 5 base pairs are always reported. Intronic variants of unknown or unlikely clinical significance are not reported beyond 5 base pairs from the splice junction. Additional Sanger sequencing is performed for any regions missing or with insufficient read depth coverage for reliable heterozygous variant detection. Reportable small insertions and deletions, potentially homozygous variants, variants in regions complicated by pseudogene interference, and single nucleotide variant calls not satisfying 100x depth of coverage and 40% het ratio thresholds are verified by Sanger sequencing.1
Gross deletion/duplication analysis is performed for the covered exons and untranslated regions of 18 genes (excluding MITF) using read-depth from NGS data with confirmatory multiplex ligation-dependent probe amplification (MLPA) and/or targeted chromosomal microarray. If a deletion is detected in exons 13, 14, or 15 of PMS2, double stranded sequencing of the appropriate exon(s) of the pseudogene, PMS2CL, will be performed to determine if the deletion is located in the PMS2 gene or pseudogene.
- Mu W, et al. Sanger confirmation is required to achieve optimal sensitivity and specificity in next-generation sequencing panel testing. J Mol Diagn. 2016. 18(6):923-932.
This test is provided by:
Frequently asked questions
- Do I need a doctor to authorise this test?
- Yes, your doctor will need to provide the sample required for this test
- Will my health insurance cover the cost of this test?
- Many health insurance plans cover the cost of genetic testing – check with your provider to find out if it is in your policy.
- How soon do I get my results?
- Usually within four to five weeks of receipt of your sample in the laboratory.
- How accurate is the test?
- Ambry follows advanced laboratory procedures and ensures quality control to deliver accurate results you can trust.